A single protein may be holding back CAR T cancer therapy

Researchers from Columbia University and University Hospital Tübingen have discovered a protein that appears to play a major role in weakening CAR T cells over time. By disabling the protein, known as NFIL3, the scientists found that these engineered immune cells remained active longer and were…

Click here to view the original article.